Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (494)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02977780 | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | recruiting | Phase 2 | 460 | David Reardon, MDOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | active not recruiting | Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06108206 |
| Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma |
| active not recruiting |
| — |
| 20 |
| Columbia UniversityOTHER |
| 1 |
| Aug 19, 2026 |
| clinicaltrials |
| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma(EF-41) | recruiting | Phase 3 | 741 | NovoCure GmbHINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT07185373 | Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL | recruiting | Phase 2 / Phase 3 | 215 | Huashan HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07762716 | Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy | not yet recruiting | Phase 1 / Phase 2 | 10 | BreakBio CorpINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04047264 | Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions | recruiting | N/A | 100 | Mayo ClinicOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04903795 | BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma(BRiTE) | recruiting | Phase 1 | 18 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06319027 | Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial(GABLE) | recruiting | Phase 2 | 100 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07767110 | Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response(TIGER-1) | not yet recruiting | Phase 1 / Phase 2 | 20 | NanOlogy, LLCINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07769918 | Hypoxia-targeted Radiotherapy Boost for GBM | not yet recruiting | N/A | 25 | NYU Langone HealthOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04755205 | A Natural History Study of Children and Adults With Olfactory Neuroblastoma | recruiting | — | 525 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05095376 | Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma | active not recruiting | Phase 3 | 265 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05859334 | Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment | active not recruiting | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06492486 | Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow(GLADIATOR) | recruiting | Phase 2 | 60 | Tata Memorial CentreOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06632236 | 5G-EMERALD: Amivantamab in Malignant Brain Tumours(5G-EMERALD) | active not recruiting | Phase 1 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06894979 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 54 | Children's Oncology GroupNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07091864 | Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma | recruiting | N/A | 116 | Mayo ClinicOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07243340 | A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor | recruiting | Phase 1 / Phase 2 | 36 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05650749 | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma(GPC2) | enrolling by invitation | Phase 1 | 45 | Stephan Grupp MD PhDOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06344130 | Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | recruiting | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07764601 | R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma(RM-MA-PD1) | not yet recruiting | N/A | 58 | WEI XUOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03962127 | MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway | active not recruiting | — | 800 | Norwegian University of Science and TechnologyOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05450744 | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)(IPAX-2) | active not recruiting | Phase 1 | 12 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT05476939 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0(BIOMEDE 2) | recruiting | Phase 3 | 433 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Aug 13, 2026 | clinicaltrials |
| NCT06186401 | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | recruiting | Phase 1 | 20 | Hideho Okada, MD, PhDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06614855 | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma | active not recruiting | Phase 1 | 12 | James Markert, MDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07052877 | The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab(GUAVA) | recruiting | — | 20 | Royal North Shore HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07172958 | Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)(SABRE) | recruiting | Phase 1 | 18 | Children's National Research InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03244995 | Mind-Body Intervention in Glioma Couples | active not recruiting | N/A | 74 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04696029 | DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | recruiting | Phase 2 | 118 | Giselle ShollerOTHER | 2 | Aug 12, 2026 | clinicaltrials |
| NCT05489887 | Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | recruiting | Phase 2 | 93 | Giselle ShollerOTHER | 4 | Aug 12, 2026 | clinicaltrials |
| NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07414979 | Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma | not yet recruiting | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07527169 | A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma | not yet recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07544992 | Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas | recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT00083512 | Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme | recruiting | — | 200 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04443829 | Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma(CAROUSEL) | active not recruiting | Phase 1 | 12 | University College, LondonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05057702 | Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma(PNOC027) | recruiting | N/A | 74 | University of California, San FranciscoOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05544526 | CAR T Cells to Target GD2 for DMG(CARMIGO) | recruiting | Phase 1 | 12 | University College, LondonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05642455 | SPEARHEAD-3 Pediatric Study | recruiting | Phase 1 / Phase 2 | 20 | USWM CT, LLCINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07100730 | Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma(IPAX BrIGHT) | recruiting | Phase 3 | 50 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT07549022 | Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor | recruiting | Phase 1 / Phase 2 | 17 | Ankit Mangla, MDOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07758062 | Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma(ELITE) | not yet recruiting | Phase 2 | 140 | Tianjin Medical University General HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04197934 | WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases | active not recruiting | Phase 1 | 56 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04469075 | Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields | active not recruiting | Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06607549 | Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)(SOLAR) | recruiting | Phase 1 | 12 | University of UtahOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07074756 | A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial | recruiting | N/A | 202 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07501559 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) | recruiting | Phase 1 / Phase 2 | 40 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07754734 | STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation | not yet recruiting | Phase 2 | 138 | Dongguan People's HospitalOTHER_GOV | 0 | Aug 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2026source: clinicaltrials